生命科学资讯

New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program

Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

FDA details rationale for rejecting rare disease gene therapy from Regenxbio

FDA explains how some copycat drugs can still win three years of exclusivity

Agilent Technologies (A) Analyst Rating Update: Morgan Stanley L - GuruFocus

[144] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan

Kyowa Kirin abandons touted eczema drug following safety review

Morgan Stanley Lowers Agilent Technologies (NYSE:A) Price Target to $160.00 - MarketBeat

GSK nabs two Frontier Biotech siRNA assets in $1B deal

Wave of deals lifts large-cap biopharma stocks

US taking a closer look at China biotech subsidies

Systimmune’s iza-bren hits phase III breast cancer goals in China

Returning to pulmonary hypertension, GSK buys 35Pharma

Pierre Fabre seeks to revive US approval chances for spurned cell therapy

Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq

EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Biohaven reduces scope of R&D cutbacks as pipeline progresses

MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit

Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug

Thermo Fisher at Raymond James Conference: Strategic Growth Insights - Investing.com